

Morris & Dickson®

2026 Biosimilars

Current Snapshot

A practical guide for prescribing and procurement decisions.



A MESSAGE TO PHYSICIANS & PHARMACISTS

Make confident care choices.

As biosimilars continue to expand across oncology, autoimmune, ophthalmology, osteoporosis, adjunctive therapy, and beyond—staying current on available options can be complex. Manufacturers, interchangeability designations, launch timing, and contract status all influence prescribing and procurement decisions.

This booklet provides a structured, scannable overview of biosimilars available through Morris & Dickson. Products are organized by therapeutic category and include key information to support clinical and operational clarity.

Our goal is simple: to serve as a reliable distribution partner while helping you navigate an evolving biosimilars landscape.

To reflect new launches, designation changes, and portfolio updates, this booklet will be updated bi-annually. We encourage you to retain this resource for reference and connect with your Morris & Dickson representative for current availability and contracting information.

Sincerely,



Michelle Korpela, PharmD

Director, Clinical & Compliance Services

Morris & Dickson.



MEET BEACONMD GPO

A Morris & Dickson partner.

BeaconMD is a specialty Group Purchasing Organization (GPO) built to support specialty clinics and infusion centers. Through its partnership with Morris & Dickson, BeaconMD delivers specialty pharmaceutical contracting support, powered by experienced distribution and customer service teams.

Designed to complement existing GPO relationships, BeaconMD helps practices expand purchasing flexibility aligned to their clinical and operational goals.

Members can now access contracted biosimilars through BeaconMD with fulfillment services provided by Morris & Dickson. Look for the  icon in the “BeaconMD Contracted” column in the charts that follow to see which biosimilars are available to you from BeaconMD.




TABLE OF CONTENTS



01 ADJUNCTIVE THERAPIES	05
02 OPHTHALMOLOGY	10
03 OSTEOPOROSIS	15
04 ONCOLOGY	19
05 AUTOIMMUNE	26



01

Adjunctive Therapies



1.1 Epogen/Procrit	06
1.2 Neulasta	07
1.3 Neupogen	09

ADJUNCTIVE THERAPIES

PROCRIT®
EPOETIN ALFA

Epoetin alfa was the first erythropoiesis-stimulating agent (ESA) approved for anemia back in 1989 with a licensing agreement differentiating **Epogen®** for anemia in dialysis patients and **Procrit®** for patients not on dialysis with kidney failure. The early 2000's brought the arrival of longer-acting ESA products that required fewer infusions. Patients receiving Epoetin alfa three times per week would only require Darbepoetin alfa once weekly. Due to competition from these long-acting ESA products and newer therapies in the hypoxia-inducible factor inhibitors (HIF Inhibitors), there are fewer biosimilar prospects in this category.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Pfizer	Retacrit	Launched 11/14/18.	<i>epoetin alfa-epbx</i>	No			
Apotex	APO-EPO/ Criticfa	Phase III clinical trials. Unclear if product development will continue.					

Legend



Yes

Inter? = Interchangeable

MDSD = Morris & Dickson
Specialty Distribution

M&D = Morris & Dickson
Full-line Distribution

ADJUNCTIVE THERAPIES



Neulasta® is a long-acting recombinant granulocyte colony-stimulating factor (G-CSF) administered after chemotherapy to prevent neutropenia. Although it was traditionally administered subcutaneously in a pre-filled syringe, pegfilgrastim is also available as both a pre-filled syringe and as an on-body injector (Neulasta Onpro®). Several manufacturers are developing on-body injectors for their biosimilar products.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Fresenius Kabi	Stimufend	Prefilled syringes launched 2/16/23. On-body injector still in progress.	<i>pegfilgrastim-fpgk</i>	No		✓	✓
Amneal	Fylnetra	Pre-filled syringes launched 5/16/23. Applying for auto-injector approval soon.	<i>pegfilgrastim-pbbk</i>	No	✓	✓	✓
Pfizer	Nyvepria	Launched 12/1/20.	<i>pegfilgrastim-apgf</i>	No		✓	
Sandoz	Ziextenzo	Launched 11/8/19.	<i>pegfilgrastim-bmez</i>	No		✓	
Accord/Intas	Udenyca	Launched 1/3/19.	<i>pegfilgrastim-cbqv</i>	No	✓	✓	

ADJUNCTIVE THERAPIES

Neulasta continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Biocon	Fulphila	Launched 7/9/18.	<i>pegfilgrastim-jmdb</i>	No			
Spectrum/Assertio	Rolvedon	Biobetter launched 10/3/22.	<i>eflapegrastim</i>	No			
Evive/Aurobindo	Ryzneuta	Biobetter launched 5/8/25.	<i>efbemalenograstim alfa</i>	No			
Apotex/Accord	Lapelga	Waiting FDA approval.					
Lupin	Armlupeg	Approved 12/1/25.	<i>pegfilgrastim-unne</i>	No			

Biobetters are not identified as such by the FDA. They are reviewed under the 351(a) Biologics License Application (BLA) pathway, so they are considered new molecular entities. They are designed to have new and improved properties over the existing biologic.

ADJUNCTIVE THERAPIES

NEUPOGEN®
(FILGRASTIM) INJECTION

Neupogen® is a shorter acting human granulocyte colony stimulating factor administered daily, typically for several days post chemotherapy to increase neutrophil counts in the body and prevent neutropenia. With the shorter half-life, dosing can be flexible for patients requiring tighter neutrophil levels. Zarxio® was the first biosimilar approved by the FDA under the 351(k) BLA pathway, which validated the biosimilar regulatory framework for the U.S.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Amneal	Releuko	Launched 2/28/22.	<i>filgrastim-ayow</i>	No	✓	✓	✓
Pfizer	Nivestym	Launched September 2018.	<i>filgrastim-aafi</i>	No		✓	
Sandoz	Zarxio	Launched 9/3/15.	<i>filgrastim-sndz</i>	No		✓	
Tanvex BioPharma	Nypozi	Launched 12/19/24.	<i>filgrastim-txid</i>	No	✓	✓	✓



02 Ophthalmology



2.1 Eylea	11
2.2 Eylea HD	13
2.3 Lucentis	14

OPHTHALMOLOGY



Eylea® is a vascular endothelial growth factor (VEGF) inhibitor administered intravitreally, typically in an Ophthalmologist's office to treat wet age-related macular degeneration. It competes with other VEGF inhibitors and compounded bevacizumab off-label, which has a much lower cost. With an aging population, overall patient utilization is expected to increase, but patent litigation may stall savings through 2027.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Samsung Bioepis/ Harrow	Opuviz	Approved 5/20/24. An agreement with Regeneron will allow the launch in January 2027.	<i>aflibercept-yszy</i>	Yes			
Biocon/Viatris	Yesafili	Approved 5/20/24. A deal with Regeneron will allow a launch in 2H 2026.	<i>aflibercept-jbvf</i>	Yes SDV No PFS			
Amgen	Pavblu	Approved 8/23/24. Launched October 2024.	<i>aflibercept-ayyh</i>	No	🕒		
Sandoz	Enzeevu	Approved 8/9/24. Litigation was settled to allow a late 2026 launch.	<i>aflibercept-abzv</i>	No			
Formycon/ Vlaorum	Ahzantive	Approved 6/28/24. Anticipated launch in 2026-2027.	<i>aflibercept-ayyh</i>	No			

OPHTHALMOLOGY

Eylea continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Celltrion	Eydenzelt	Approved 10/9/25. A settlement allows the launch on 12/31/26.	<i>aflibercept-boav</i>	No			
Alvotech/Teva	AVT06	CRL received in Nov 2025. An agreement will allow a Q4 2026 launch.					
Rophibio/ Amicogen	RBS-001	Phase III clinical trials.					
San Chun Dang/ Fresenius Kabi	SCD411	Pending FDA approval.					

OPHTHALMOLOGY



Eylea HD® is a high-dose formulation that allows for administration every 8-16 weeks instead of every 8 weeks with Eyla. The extended dosing interval may protect Eylea from biosimilar market share erosion.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Alvotech/Teva	AVT29	Anticipated to file for FDA approval in 2026.					

OPHTHALMOLOGY



Lucentis® is a vascular endothelial growth factor (VEGF) inhibitor often used for wet age-related macular degeneration. Utilization has decreased over time with Eylea being the market leader in this category. Despite Cimerli having top market share for ranibizumab products, Formycon announced a temporary one year pause on commercialization as they look at alternative strategies due to a large decrease in the ASP over prior year. Lucentis regained nearly all of its market share during the Cimerli pause. In early 2026, Formycon launched a new ranibizumab biosimilar with Zydus.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Sandoz/Formycon	Cimerli	Commercialization paused in February 2025.	<i>ranibizumab-eqrn</i>	Yes			
Samsung Bioepis	Byooviz	Launched 6/2/22.	<i>ranibizumab-nuna</i>	Yes			
Formycon/Zydus	Nufymco	Approved 12/18/25 with a potential 2026 launch.	<i>ranibizumab-leyk</i>	Yes			
Xbrane	Lucamzi	After multiple complete response letters, Xbrane resubmitted for FDA approval in early 2026.					
Lupin	LUBT010	Pending FDA approval.					



03 Osteoporosis



3.1 Prolia 16

3.2 Xgeva 18

OSTEOPOROSIS



Prolia® is a RANKL inhibitor used to inhibit osteoclast bone destruction in patients with osteoporosis. There may be more than 10 biosimilars (both branded and unbranded) to Prolia launching between 2025-2026. This is expected to drive additional rebates and deeper WAC discounts in the fight for market share. Since Prolia is often billed under the medical benefit, it is not expected to see PBMs utilize private-label biosimilars. Osteoporosis prevalence is expected to increase with the aging population, but bisphosphonates are expected to maintain their place as first line therapy due to cost.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Sandoz	Jubbonti	Launched 6/2/25.	<i>denosumab-bbdz</i>	Yes	☑	☑	☑
Samsung Bioepis	Ospomyv	Launched 10/23/25.	<i>denosumab-dssb</i>	Yes			
Celltrion	Stoboclo	Launched 7/7/25.	<i>denosumab-bmwo</i>	Yes	☑	☑	☑
Fresenius Kabi	Conexxence	Launched 7/1/25. Unbranded labeling approved by the FDA.	<i>denosumab-bnht</i>	Yes		☑	☑
Organon/Henlius	Bildyos	Launched 9/11/25.	<i>denosumab-nxxp</i>	Yes		☑	
Amneal/ mAbxience	Boncresa	Approved 12/19/25 with plans to launch in 2026.	<i>denosumab-mobz</i>	Yes			

OSTEOPOROSIS

Prolia continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Biocon	Bosaya	Approved 9/16/25.	<i>denosumab-kyqq</i>	Yes			
Dr. Reddy's/ Alvotech	AVT03	CRL received in late 2025 and no announcement has been made for future plans.					
Hikma	Enoby	Launched 1/19/26.	<i>denosumab-qbde</i>	Yes			
Teva	TVB-009P	CRL received in July 2025.					
Enzene/Alkem Labs	ENZ215	Under FDA review. Alkem expects to launch in late 2026.					
Accord	Osvytri	Approved 11/20/25.	<i>denosumab-desu</i>	Yes			
CuraTeQ/ Aurobindo	BP16	Phase III clinical trials. Aurobindo plans to submit to the FDA in mid-2026.					
JHL Biotech/Eden Biologics	EB1001	Phase III clinical trials.					
Luye/Boan Biotech	LY06006	Phase III clinical trials. Luye expects to file for FDA approval in 2026.					

OSTEOPOROSIS

XGEVA®
(denosumab) injection

Xgeva® is also a form of denosumab that was developed by Amgen, along with Prolia. Xgeva is indicated for cancer-related bone loss, which is often much more aggressive, thus requiring higher and more frequent dosing. Subcutaneous administration provides a differentiator compared to competing products which are also facing increased generic competition similar to the biosimilar growth for Xgeva.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Sandoz	Wyost	Launched 6/2/25.	<i>denosumab-bbdz</i>	Yes	✓	✓	✓
Samsung Bioepis	Xbryk	FDA approved but not launched.	<i>denosumab-dssb</i>	Yes			
Celltrion	Osenvelt	Launched 7/7/25.	<i>denosumab-bmwo</i>	Yes	✓	✓	✓
Fresenius Kabi	Bomynta	Launched 7/1/25.	<i>denosumab-bnht</i>	Yes		✓	✓
Organon/Henlius	Bilprevda	Launched 9/11/25.	<i>denosumab-nxxp</i>	Yes		✓	
Hikma	Xtrenbo	Launched 1/19/26.	<i>denosumab-qbde</i>	Yes	✓		
Accord	Jubereq	Approved 11/20/25.	<i>denosumab-desu</i>	Yes			
Biocon	Aukelso	Approved 9/16/25.	<i>denosumab-kyqq</i>	Yes			
Amneal/mAbxience	Oziltus	Approved 12/19/25 with plans to launch in 2026.	<i>denosumab-mobz</i>	Yes			



04 Oncology



4.1 Avastin	20
4.2 Herceptin	22
4.3 Perjeta	24
4.4 Rituxan	25

ONCOLOGY

AVASTIN®

Avastin® is a vascular endothelial growth factor (VEGF) inhibitor administered intravenously for several types of cancers and is frequently compounded to be used off-label to treat macular degeneration with intravitreal injection. With several biosimilars on the market, payers have readily implemented preferred biosimilar access on their formularies. Earlier biosimilar entrants currently have better formulary exposure. Because several of the biosimilar manufacturers also have additional oncolytics, some payers are driving deeper negotiated savings by preferring one manufacturer for all biosimilar products to be on formulary.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Biocon	Jobevne	Launched 9/15/25.	<i>bevacizumab-nwgd</i>	No			
Genentech	Avziri	Approved December 2023 but not launched.	<i>bevacizumab-tnjn</i>	No			
Celltrion	Vegzelma	Launched March 2023.	<i>bevacizumab-adcd</i>	No			
Amneal	Alymsys	Launched October 2022.	<i>bevacizuman-maly</i>	No			
Pfizer	Zirabev	Launched 12/31/19.	<i>bevacizumab-bvzr</i>	No			
Amgen	Mvasi	Launched 7/18/19.	<i>bevacizumab-awwb</i>	No			

ONCOLOGY

Avastin continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
TeRuisi	TRS003	Phase III clinical trials.					
Centus/ AstraZeneca	FKB238	Pending FDA approval					
Samsung Bioepis	Aybintio	Phase III clinical trials.					
Prestige BioPharma	HD204	Phase III clinical trials					
Henlius	HLX04	Pending FDA approval in late 2026					

ONCOLOGY



Herceptin® is an anti-HER2 antibody in which the HER2 protein is overexpressed, which typically causes aggressive tumor growth. It was one of the first targeted biologic therapies helping to bring the future of biomarker-driven treatment in precision oncology. Herceptin and its biosimilars are given by intravenous infusion. As biosimilar adoption has increased, two new subcutaneous products (Herceptin Hylecta and Phesgo) have launched that may have more favorable administration for patients and provide competition to the biosimilar market. Not all biosimilar trastuzumab products share the same indications as the reference product.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Amgen/Allergan	Kanjinti	Launched 7/18/19.	<i>trastuzumab-anns</i>	No	✓		
Pfizer	Trazimera	Launched 2/18/20.	<i>trastuzumab-qyyp</i>	No		✓	
Organon	Ontruzant	Launched 4/15/20.	<i>trastuzumab-dttb</i>	No		✓	
Teva/Celltrion	Herzuma	Launched 3/16/20.	<i>trastuzumab-pkrb</i>	No		✓	✓
Mylan/Biocon	Ogivri	Launched 12/2/19.	<i>trastuzumab-dkst</i>	No		✓	✓
Accord BioPharma	Hercessi	Launched 1/1/25	<i>trastuzumab-strf</i>	No	✓	✓	

ONCOLOGY

Herceptin continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Sandoz/EirGenix	EG12014	Received a CRL in December 2022 and again in December 2025.					
Tanvex BioPharma	TX05	Received a CRL in July 2022 and again in January 2025.					
Han Wha Pharma	HD201	Phase III clinical trials					

ONCOLOGY



Perjeta® is an intravenous targeted therapy used in HER-2 positive metastatic breast cancer. It is used in combination with trastuzumab as a standard of care. As trastuzumab biosimilars expand, Perjeta use has declined in favor of a subcutaneous pertuzumab-combination product (Phesgo®) that can significantly reduce administration time.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Organon/Henlius	Poherdy	Approved 11/13/25, but due to settlement agreements, a projected launch is not expected until 2028.	<i>pertuzumab-dpzb</i>	Yes			
Biocon	PERT-IJS	Pending FDA approval					

ONCOLOGY

Rituxan®
Rituximab

Rituxan® is a targeted therapy for both oncology and autoimmune disorders and is listed on the WHO Essential Medicines List. It is a monoclonal antibody that targets CD20 proteins on B cells to eliminate abnormal B cells. It is administered via IV infusion. A subcutaneous formulation, Rituxan Hycela (rituximab and hyaluronidase) was developed, for which there are no biosimilars. The Rituxan biosimilars are not approved for all of the same indications as the originator product. Rituxan utilization is expected to continue to decline in favor of lower cost products.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Amgen	Riabni	Launched 1/1/21.	<i>rituximab-arrx</i>	No			
Pfizer	Ruxience	Launched 1/23/20.	<i>rituximab-pvvr</i>	No			
Teva	Truxima	Launched 11/11/19.	<i>rituximab-abbs</i>	No			
Dr. Reddy's	DRL RI	Received a CRL in early 2024.					



05 Autoimmune



5.1 Actemra	27
5.2 Enbrel	29
5.3 Humira	30
5.4 Lantus	32
5.5 Novolog	33
5.6 Orencia	34
5.7 Remicade	35
5.8 Soliris	36
5.9 Stelara	37
5.10 Tysabri	38
5.11 Xolair	39

AUTOIMMUNE



Actemra® is an antagonist of the interleukin-6 (IL-6) receptor that leads to cytokine reduction. Tofidence® was the first Actemra biosimilar approved for IV administration. Tyenne followed and has both IV and SC administration with the same Tofidence indications. The SC formulation has gained popularity with patients due to the ease of self-administration. Rheumatoid arthritis is the most common indication for which Actemra is used. However, rheumatoid arthritis has several other therapies, including lower priced biosimilars, that have helped demonstrate significant acceptance of biosimilar products. Actemra sales also grew during the COVID-19 pandemic due to a new indication in hospitalized COVID-19 patients.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Organon	Tofidence (IV)	Launched 5/6/24.	<i>tocilizumab-bavi</i>	No		✓	
Fresenius Kabi	Tyenne (IV)	Launched 4/15/25.	<i>tocilizumab-aazg</i>	No		✓	✓
Celltrion	Avtozma (IV)	Launched 10/3/25.	<i>tocilizumab-anoh</i>	Yes	✓	✓	✓
Fresenius Kabi	Tyenne (SC)	Launched 7/2/24.	<i>tocilizumab-aazg</i>	No		✓	
Celltrion	Avtozma (SC)	Launched 3/16/26.	<i>tocilizumab-anoh</i>	Yes			

AUTOIMMUNE

Actemra continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Dr. Reddy's/Coya Therapeutics	DRL_TC	Phase III clinical trials for both SC and IV formulations.					
Bio-Thera/Biogen	Tofidence SC	Phase I clinical trials for the SC formulation.					

AUTOIMMUNE



Enbrel® is a TNF inhibitor with a wide range of inflammatory and immunologic indications. Despite having two approved biosimilars, none have launched in the U.S. and analysts predict no launch will occur until 2028-2029. Biosimilar competition from other TNF inhibitors is expected to drive formulary management more than Enbrel biosimilars and may lessen annual price increases.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Samsung Bioepis	Eticovo	Approved April 2019. Not launched.	<i>etanercept-ykro</i>	Yes			
Sandoz	Erelzi	Approved 8/30/16. Not launched.	<i>etanercept-szzs</i>	No			
Lupin	YLB113	Phase III clinical trials completed February 2018, but likely due to the second patent expiration in 2029. FDA approval not yet sought.					

AUTOIMMUNE



Humira® is a TNF inhibitor with more indications than any competitor in that category and dominates the market share despite being third to market. Humira is the innovator product with the most biosimilars, but biosimilar sales really only started to accelerate after CVS Caremark removed coverage for Humira in April 2024. Other payers are continuing this strategy as biosimilar adoption becomes more accepted by patients. Biosimilar products differ in their strengths and formulations available.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Celltrion	Yuflyma	Launched 7/2/23.	<i>adalimumab-aaty</i>	Yes		⊙	
Fresenius Kabi	Idacio	Announced they would no longer sell in U.S. after 4/1/25 due to commercial reasons.	<i>adalimumab-aacf</i>	No			
Meitheal	Yusimry	Launched 7/3/23.	<i>adalimumab-aqvh</i>	No		⊙	
Biocon	Hulio	Launched 7/3/23.	<i>adalimumab-fkjp</i>	Yes		⊙	
Pfizer	Abrilada	Launched 10/18/23.	<i>adalimumab-afzb</i>	Yes		⊙	
Organon	Hadlima	Launched 7/1/23.	<i>adalimumab-bwwd</i>	Yes		⊙	
Sandoz	Hyrimoz	Launched 10/2/23.	<i>adalimumab-adaz</i>	Yes		⊙	

AUTOIMMUNE

Humira continued

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Boehringer Ingelheim	Cyltezo	Launched 7/1/23.	<i>adalimumab-adbm</i>	Yes			
Amgen	Amjevita	Launched 1/31/23.	<i>adalimumab-atto</i>	Yes			
Teva	Simlandi	Launched 5/20/24.	<i>adalimumab-ryvk</i>	Yes			
Mylan/Biocon	MYL-1401A	Phase III clinical trials.					

AUTOIMMUNE



Lantus® is a long-acting human insulin available in both vial and pen form. Insulin pricing has faced public scrutiny over the past several years. The Inflation Reduction Act now limits insulin copay for Medicare Part D beneficiaries, along with many states that have capped out-of-pocket insulin costs for patients. Together with biosimilar adoption, this has greatly decreased the list price for these products.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Eli Lilly	Rezvoglar	Launched 3/6/23.	<i>insulin glargine-aglr</i>	Yes		✓	
Biocon	Semglee	Launched 11/15/21.	<i>insulin glargine-yfgn</i>	Yes		✓	
Gan & Lee/ Sandoz	GL-GLA	Pending FDA approval.					

AUTOIMMUNE



Novolog® is a rapid-acting insulin, typically administered immediately before a meal for glycemic control. The high cost of insulin has been a political talking point in the U.S., where diabetic patients often ration their own insulin supply due to cost. Biosimilars will be available in both pen and vial formulation.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Sanofi-Aventis	Merilog	Launched July 2025.	<i>insulin aspart-szjj</i>	No		✓	
Biocon	Kirsty	Launched September 2025.	<i>insulin aspart-xjhz</i>	Yes		✓	
Amphastar	AMP-004	Phase II/III clinical trials complete. Amphastar sought interchangeability status from FDA. Application submitted but approval not expected until late 2026.					
Gan & Lee/Sandoz	GL-ASP	Pending FDA approval.					

AUTOIMMUNE



Orencia® was a first-in-class selective co-stimulation modulator to inhibit T-cell activation, which is part of the pathogenesis. It is a disease-modifying antirheumatic drug available as both an IV and SC formulation with its primary use being for rheumatoid arthritis (RA). However, it is typically second-line therapy for RA due to the competitive space of TNF inhibitors, IL antagonists, and JAK inhibitors, many of which have lower cost biosimilars already available. It is unclear when an Orencia biosimilar will launch.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Dr. Reddy's	DRL_AB IV	Pending FDA approval in late 2026/early 2027					
Kashiv Biosciences	KSHB003	Phase I clinical trial completed in early 2025.					

AUTOIMMUNE



Remicade® was the first TNF inhibitor in the U.S. and the first to face biosimilar competition. Relatively slow uptake of infliximab biosimilars made the industry initially question whether biosimilar savings would materialize after Remicade managed to maintain market share. Now, formulary management is the primary driver of TNF inhibitors because it is such a saturated market. Remicade is administered by intravenous infusion, as are the biosimilar infliximab products. Zymfentra®, a biobetter approved under a unique BLA, is available as a subcutaneous self-injection of infliximab.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Amgen	Avsola	Launched May 2020.	<i>infliximab-axxq</i>	No			
Pfizer	Ixifi (not launching in U.S.)	Approved by FDA in April 2017, but Pfizer decided to not launch product in U.S. as they already had Inflectra based.	<i>infliximab-qbtx</i>	No			
Organon	Renflexis	Launched 7/24/17.	<i>infliximab-abda</i>	No			
Pfizer	Inflectra	Launched 10/3/16.	<i>infliximab-dyyb</i>	No			
Celltrion	Zymfentra	Biobetter launched 3/15/24 for subset of Remicade indications.	<i>infliximab-dyyb</i>	No			

AUTOIMMUNE



Soliris® is a monoclonal antibody that binds to the complement C5 protein to inhibit activation of the complement system in the body's immune system and prevents breakdown of red blood cells. These products all utilize a REMS program to mitigate the risk of meningococcal infections. Soliris biosimilars were the first to be approved to treat certain rare diseases. With a smaller potential patient population, the effects of biosimilar adoption may not be as noticeable.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Amgen	Bkemv	Launched 4/2/25.	<i>eculizumab-aeeb</i>	Yes	⌚		
Teva	Epysqli	Launched 4/7/25.	<i>eculizumab-aagh</i>	Yes	⌚		⌚

AUTOIMMUNE



Stelara® is a human interleukin-23 and interleukin-23 antagonist available in both IV and SC formulations to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. By blocking these proteins, it helps reduce inflammation. With such a large pool of biosimilars, many have launched at significant discounts to WAC. As of July 2025, some large payers have begun to exclude branded Stelara in favor of biosimilar products. Wezlana autoinjectors are not interchangeable, but vials and prefilled syringes are interchangeable.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	Dropship	BeaconMD Contracted
Amgen	Wezlana	Launched 1/1/25.	ustekinumab-auub	Yes SVD No PFS autoinjector			⊙	
Teva	Selarsdi	Launched 2/21/25.	ustekinumab-aekn	Yes		⊙		
Fresenius Kabi	Otulfi	Launched 3/3/25.	ustekinumab-aauz	Yes		⊙		⊙
Accord	Imuldosa	Launched 7/2/25.	ustekinumab-srlf	No	⊙	⊙		
Biocon	Yesintek	Launched 2/24/25.	ustekinumab-kfce	Yes		⊙		⊙
Celltrion	Steqeyma	Launched 3/12/25.	ustekinumab-stba	Yes	⊙	⊙		⊙
Sandoz	Pyzchiva	Launched 2/24/25.	ustekinumab-ttwe	Yes	⊙	⊙		⊙
Hikma	Starjemza	Launched 11/6/25.	ustekinumab-hmny	Yes	⊙			

AUTOIMMUNE



Tysabri® is an integrin receptor antagonist used to treat multiple sclerosis (MS) and Crohn's disease via IV infusion every four weeks. It also includes a warning label for Progressive Multifocal Leukoencephalopathy (PML). With additional therapies that have little to no risk of PML, neurologists have tended to favor alternative products except for the most severe cases of MS and even then, try to limit therapy to two years to reduce the risk.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Sandoz	Tyruko	Approved 8/24/23. Launched 11/17/25.	<i>natalizumab-sztn</i>	No			

AUTOIMMUNE



Xolair® is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to immunoglobulin E. Since its approval in 2003, it has seen expanded indications for asthma-related add-ons, and increased competition from several interleukin inhibitors and lower cost therapies. Xolair became the first medication to reduce allergic reactions to foods in 2024 with the indication for IgE-mediated food allergy in patients as young as 1 year-old. This should help offset lost sales until the 2026 potential launch of Omlyclo and its unbranded formulation.

Manufacturer	Brand Name	Status	Generic Name	Inter?	MDSD	M&D	BeaconMD Contracted
Celltrion	Omlyclo	Approved 3/7/25. Anticipated to launch in 2026.	<i>omalizumab-igec</i>	Yes			
Amneal/Kashiv BioSciences	ADL-018	Pending FDA approval with a potential 2027 launch.					
Aurobindo/CuraTeQ	BP11	Phase III clinical trials. Aurobindo expects to file for FDA approval in late 2026.					
Teva	TEV-45779	Phase III clinical trials. Teva expects to launch in 2026 or 2027.					

Partner with Morris & Dickson for your biosimilar needs.

Morris & Dickson supports specialty practices, infusion centers, and health systems with broad biosimilars availability and dependable distribution. For therapy-specific product availability, contract status, or ordering guidance, connect directly with your representative.

Source: IPD Analytics. Global Life-Cycle Insights; Market & Financial Insights. Last updated May 2026.



Morris & Dickson®

Contact Sales

✉ sales@morrisdickson.com

☎ (800) 388-3833

🌐 www.morrisdickson.com